Discovery and Enzyme Kinetic Characterization of Novel CYP2D6 Variants

被引:0
|
作者
Zhong, Yun-shan [1 ]
Kong, Qi-hui [1 ]
Wang, Jing [1 ]
Ye, Feng [1 ]
Li, Xin-yue [1 ]
Zhang, Li-qun [2 ]
Dai, Da-peng [2 ]
Hu, Guo-xin [1 ]
Cai, Jian-ping [2 ]
Qian, Jian-chang [1 ]
Ji, Fu-sui [2 ,3 ]
机构
[1] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China
[2] Chinese Acad Med Sci, Beijing Hosp, Beijing Inst Geriatr, Inst Geriatr Med,Key Lab Geriatr,Natl Ctr Gerontol, Beijing 100005, Peoples R China
[3] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol,Dept Cardiol, Beijing 100005, Peoples R China
基金
中国国家自然科学基金;
关键词
CYTOCHROME-P450; 2D6; POLYMORPHISM; GENE; ALLELES;
D O I
10.1021/acs.chemrestox.4c00298
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cytochrome P450 2D6 (CYP2D6) exhibits rich genetic polymorphism, and functional changes caused by variations are the key reasons for differences in substrate drug systemic exposure. Discovering novel variants and defining their enzymatic kinetic characteristics can contribute to the personalized application of drugs. In this study, a data chain of variant-function-structure was established through population-based sequencing, baculovirus insect cell expression, in vitro enzymatic incubation, and ultrahigh performance liquid chromatography tandem mass spectrometry. Results revealed nine novel missense mutations in the exonic regions. After the corresponding microsomes were obtained, the kinetics of the variants were investigated using dextromethorphan as a probe substrate. It was found that the activities of CYP2D6.2, 10, 17, 35, 65, R28G, T76M, and E215K were significantly reduced, while D301V almost led to loss of enzyme function. Additionally, the relative clearance rate of R25Q was significantly increased. From the molecular structure perspective, the mutation sites are distributed outside the dextromethorphan binding pocket, suggesting that they primarily influence CYP2D6 activity via allosteric modulation. These research findings provide fundamental data for the precise application of CYP2D6 substrate drugs.
引用
收藏
页码:1903 / 1910
页数:8
相关论文
共 50 条
  • [41] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [42] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [43] Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual
    Andrea Gaedigk
    Dorothee Frank
    Uwe Fuhr
    European Journal of Clinical Pharmacology, 2009, 65 : 97 - 100
  • [44] CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
    Molden, Espen
    Jukic, Marin M.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [45] Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation
    Saito, Takahiro
    Rico, Evelyn Marie Gutierrez
    Kikuchi, Aoi
    Kaneko, Akira
    Kumondai, Masaki
    Akai, Fumika
    Saigusa, Daisuke
    Oda, Akifumi
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (06) : 250 - 257
  • [46] Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual
    Gaedigk, Andrea
    Frank, Dorothee
    Fuhr, Uwe
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (01) : 97 - 100
  • [47] Human liver CYP2D6 genotype, full-length mRNA, and activity, assessed with a novel CYP2D6 substrate
    Bodor, M
    McConnachie, L
    Kowdley, K
    Levy, A
    Tun, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DD
    Ho, RJY
    DRUG METABOLISM REVIEWS, 2004, 36 : 113 - 113
  • [48] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [49] CYP2D7-2D6 HYBRID+CYP2D6*2 TANDEMS: IDENTIFICATION OF NOVEL CYP2D6 DUPLICATION ARRANGEMENTS
    Gaedigk, A.
    Frank, D.
    Johnson, C.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S47 - S47
  • [50] Novel CYP2D6 alleles in African Americans.
    Gaedigk, A
    Leeder, JS
    Bradford, LD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P94 - P94